Charcot Neuroarthropathy After Simultaneous Pancreas-Kidney Transplant

• DOI: 10.1097/tp.0b013e31825cadbb
• Publication Date: 2012-08-28T10:06:44Z
• Authors: Érika B. Rangel; João R. Sá; Samirah A. Gomes; Aluizio B. Carvalho; Cláudio S. Melaragno; Adriano M. Gonzalez; Marcelo M. Linhares; Jose O. Medina-Pe...
• Keywords: Graft Rejection; Male; Time Factors; Risk Assessment; 03 medical and health sciences; 0302 clinical medicine; Risk Factors; Foot Joints; Pancreas-kidney transplantation; Humans; Nonvertebral fractures; Glucocorticoids; Retrospective Studies; Dose-Response Relationship, Drug; Charcot neuroarthropathy; Kidney Transplantation; Magnetic Resonance Imaging; 3. Good health; Radiography; Diabetes Mellitus, Type 1; Treatment Outcome; Female; Pancreas Transplantation; Arthropathy, Neurogenic; Immunosuppressive Agents

Background Immunosuppressive regimen is associated with several metabolic adverse effects. Bone loss and fractures are frequent after transplantation involve multifactorial mechanisms. Methods A retrospective analysis of 130 patients submitted to simultaneous pancreas-kidney (SPKT) an identification risk factors involved in de novo Charcot neuroarthropathy by multivariate were used; P<0.05 was considered significant. Results diagnosed 4.6% SPKT recipients during the first year. Cumulative glucocorticoid doses (daily dose plus methylprednisolone pulse) 6 months both adjusted body weight (>78 mg/kg) not (P=0.001 P<0.0001, respectively). Age, gender, race, time on dialysis, diabetes history, posttransplantation hyperparathyroidism related SPKT. Conclusions Glucocorticoids main for Protocols including avoidance or minimization should be considered.